# 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

> **NCT00275444** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 216 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir

## Key facts

- **NCT ID:** NCT00275444
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-29
- **Primary completion:** 2003-01-20
- **Final completion:** —
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275444, "3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00275444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*